21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

Close this search box.

American Society of Hematology (ASH) Annual Meeting Update

14 December, 2016

Several presentations were delivered by independent experts at the prestigious 58th ASH Annual Meeting that summarised studies using Resonance Health’s FerriScan® technology. The studies demonstrated the broadening acceptance of FerriScan in iron monitoring and management and included results from the multicentre US TWiTCH study (click here to read the abstract) and from China’s Guangxi Medical University (click here to read the abstract).

Resonance Health team members recently joined more than 20,000 haematology professionals at the ASH Annual Meeting in San Diego, California. The meeting is the world's premier event in malignant and non-malignant haematology and provided an invaluable educational experience and the opportunity to network with top minds in the field.

The team was also very happy to use the opportunity to meet with new and long-standing pharmaceutical industry partners, medical key opinion leaders, and patient advocacy groups to share knowledge and support greater access to Resonance Health’s leading technologies. The team also held an evening symposium to explore further the role of FerriScan and HepaFat-Scan in the management of health of cancer survivors.

An oral presentation by Dr Banu Aygun from the Cohen Children’s Medical Center, New York, demonstrated how FerriScan can be used to monitor iron unloading by therapeutic phlebotomy in previously transfused children with sickle cell disease (SCD). The data, derived from the TWiTCH study, provided further clinical evidence for use of FerriScan for the management of patients in this cohort.

Further FerriScan data from clinicians at Guangxi Medical University, China, was also presented at the lively ASH poster session by Dr Rong rong Liu, demonstrating the prevalence and severity of iron burden in non-transfusion-dependant thalassaemia (NTDT) in China. The abstract concluded that the first FerriScan assessment should be performed as early as 5 years old, emphasising the importance of the technology in this patient cohort. To read the abstract please click here.

Professor Tim St. Pierre, Resonance Health’s Chief Scientific Officer, commented on the success of the conference:

The conference is a vital platform for us to share our expertise as global leaders in this field with FerriScan remaining the only FDA approved, standardised technology for accurate non-invasive measurement of liver iron concentration… We are delighted with the opportunities we will now be pursuing into 2017 as a result of this very successful conference.”

If you are interested in further information regarding the conference please email: melanieb@resonancehealth.com.